ONCAlert | 2018 ASCO Annual Meeting

An Overview of a Study Exploring Mirvetuximab Soravtansine in Ovarian Cancer

Kathleen N. Moore, MD
Published Online: 11:54 PM, Sun June 4, 2017

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses results of an ongoing clinical trial exploring mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in platinum-resistant epithelial ovarian cancer patients, during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.